NovaBridge officer to sell 46,947 shares

An executive of NovaBridge Biosciences files to sell a portion of recently vested equity on NASDAQ mainly to cover obligations from equity award vesting.

Rhea-AI Filing Summary

NovaBridge Biosciences (NBP) received a notice under Rule 144 that Chief Business Development Officer Cao Sean Wuxiong plans to sell 46,947 Ordinary Shares through Citigroup Global Markets on or about September 9, 2026 on NASDAQ, with an aggregate market value of $79,377.99 and 265,377,891 shares outstanding.

The shares derive from restricted stock units vesting on September 3, 2026, when 147,554 shares were acquired as compensation, and the filing states that shares are being sold to cover obligations arising from the vesting and settlement of equity awards.

Key Figures

Shares to be sold: 46,947 shares Aggregate market value: $79,377.99 Shares outstanding: 265,377,891 shares +3 more

6 metrics

Shares to be sold 46,947 shares Ordinary Shares proposed to be sold under Rule 144

Aggregate market value $79,377.99 Aggregate market value of the 46,947 shares to be sold

Shares outstanding 265,377,891 shares Number of NovaBridge Biosciences shares outstanding referenced in the notice

Shares acquired via RSU vesting 147,554 shares Ordinary Shares acquired on September 3, 2026 as compensation from restricted stock units vesting

Approximate sale date September 9, 2026 Approximate date of sale for the proposed Rule 144 transaction

Acquisition date September 3, 2026 Date the RSU-based Ordinary Shares were acquired as compensation

Key Terms

Rule 144, restricted stock units, aggregate market value, equity awards

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"Ordinary Shares | 09/03/2026 | RESTRICTED STOCK UNITS VESTING |"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate market value financial

"Ordinary Shares | CITIGROUP GLOBAL MARKETS ... | 46947 | 79377.99 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

equity awards financial

"SHARES WERE SOLD TO COVER OBLIGATIONS ARISING FROM THE VESTING AND SETTLEMENT OF EQUITY AWARDS"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does NovaBridge Biosciences (NBP) Form 144 filing report?

It reports that Chief Business Development Officer Cao Sean Wuxiong intends to sell 46,947 Ordinary Shares of NovaBridge Biosciences on NASDAQ under Rule 144, with an aggregate market value of $79,377.99, through Citigroup Global Markets.

How many NovaBridge Biosciences (NBP) shares are planned to be sold under this Form 144?

The notice states that 46,947 Ordinary Shares of NovaBridge Biosciences are proposed to be sold. These shares have an aggregate market value of $79,377.99 as stated in the filing.

When are the NBP shares expected to be sold according to the Form 144?

The approximate sale date disclosed is September 9, 2026. The filing lists NASDAQ as the securities exchange and Citigroup Global Markets as the broker handling the transaction.

How were the NovaBridge Biosciences (NBP) shares being sold acquired?

The filing states the Ordinary Shares were acquired on September 3, 2026 through restricted stock units vesting from NovaBridge Biosciences, described as compensation in the securities-to-be-sold section.

What amount of NovaBridge Biosciences (NBP) shares vested as compensation?

The securities-to-be-sold section reports that 147,554 Ordinary Shares were acquired on September 3, 2026 via restricted stock units vesting, characterized as compensation from NovaBridge Biosciences.

Why does the Form 144 say the NBP shares are being sold?

The remarks state that shares were sold to cover obligations arising from the vesting and settlement of equity awards, indicating the sale relates to obligations linked to those equity awards.

How many NovaBridge Biosciences (NBP) shares are outstanding as referenced in the filing?

The filing lists 265,377,891 shares of NovaBridge Biosciences as outstanding in the securities information section, providing context for the planned sale amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 02:48 PM EDT Accepted by SEC EDGAR 09/09/2026 - 02:48 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002109966
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NovaBridge Biosciences
SEC File Number	001-39173
Address of Issuer	SUITE 400, 2440 RESEARCH BLVD ROCKVILLE MARYLAND 20850
Phone	(301) 670 2800
Name of Person for Whose Account the Securities are To Be Sold	Cao Sean Wuxiong
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	CHIEF BUSINESS DEVELOPMENT OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	46947	79377.99	265377891	09/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	09/03/2026	RESTRICTED STOCK UNITS VESTING	NOVABRIDGE BIOSCIENCES			147554	09/09/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SHARES WERE SOLD TO COVER OBLIGATIONS ARISING FROM THE VESTING AND SETTLEMENT OF EQUITY AWARDS
Date of Notice	09/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)